Cantor Fitzgerald lifted its price target for ARS Pharmaceuticals, Inc. on June 1, 2026.
2 reports, 1 independent
Updated Sep 13
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald lifted its price target for ARS Pharmaceuticals, Inc. on June 1, 2026.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Leerink and Cantor Fitzgerald set price targets for ARS; class action lawsuit promoted.1 source
Cantor Fitzgerald raises price target for ARS Pharmaceuticals.1 source
Keep exploring
The entities involved
-
Cantor Fitzgerald
American financial services company
Related events
- Cantor Fitzgerald raised its price target and rating for Supernus Pharmaceuticals, Inc. on September 2, 2026, and the company filed a disclosure with the SEC.
- Cantor Fitzgerald raised its price target on Salesforce on September 1, 2026.
- Cantor Fitzgerald and Wells Fargo raised price targets for Regeneron Pharmaceuticals stock.
- Cantor Fitzgerald, Morgan Stanley, and Royal Bank of Canada issued price target updates for Elevance Health, Inc. on September 12, 2026.
- Cantor Fitzgerald raised its price target on Texas Instruments shares on July 8, 2026.